Featured Research

from universities, journals, and other organizations

New Class Of Targeted Cancer Drugs Shows Promise In Slowing Progression Of Recurrent Prostate Cancer

Date:
February 27, 2007
Source:
Cedars-Sinai Medical Center
Summary:
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows.

A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.

The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.

"Advanced prostate cancer is difficult to treat -- and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment," said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinai's Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. "Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow -- not stop or shrink -- tumor growth."

"The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time," said Agus. "Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups."

Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.

While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.

Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.

In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.

The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.

Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estimates that there will be about 218,890 new cases of prostate cancer in the United States in 2007 and that approximately 27,050 men will die of this disease.

Other institutions that participated in the study included Arizona Cancer Center, the Cleveland Clinic Foundation, Indiana University, Memorial Sloan-Kettering Cancer Center and the University of Wisconsin, Madison.

The research was supported by Genentech, Inc. and the National Cancer Institute Specialized Program of Research Excellence (SPORE) program.


Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Cedars-Sinai Medical Center. "New Class Of Targeted Cancer Drugs Shows Promise In Slowing Progression Of Recurrent Prostate Cancer." ScienceDaily. ScienceDaily, 27 February 2007. <www.sciencedaily.com/releases/2007/02/070218140145.htm>.
Cedars-Sinai Medical Center. (2007, February 27). New Class Of Targeted Cancer Drugs Shows Promise In Slowing Progression Of Recurrent Prostate Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/02/070218140145.htm
Cedars-Sinai Medical Center. "New Class Of Targeted Cancer Drugs Shows Promise In Slowing Progression Of Recurrent Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/02/070218140145.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins